Phase 1 · NCT06313528
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction
CompletedVerified
Registry record
Trial details
- Trial
- A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
- ClinicalTrials.gov ID
- NCT06313528
- Indication
- Obesity
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 85
- Status
- Completed
- Interventions
- Drug: LY3437943; Other: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – 60 Years
- Locations
- 3 sites · United States
- Study start
- 20 Mar 2024
- Primary completion
- 26 Aug 2025
- Study completion
- 26 Aug 2025
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 23 Sept 2025
Endpoints
Primary
Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)
Secondary
Change from Baseline in Sleep Metabolic Rate (SMR); Change from Baseline in SMR; Change from Baseline in 24-hour Energy Expenditure (EE); Change from Baseline in 24-hour EE; Change from Baseline in Total Calorie Intake at Lunch; Change from Baseline in Total Calorie Intake at Dinner; Change from Baseline in Fasting Appetite Visual Analog Score (VAS)